LEFLUNOMIDE tablet

Land: USA

Sprog: engelsk

Kilde: NLM (National Library of Medicine)

Aktiv bestanddel:

LEFLUNOMIDE (UNII: G162GK9U4W) (LEFLUNOMIDE - UNII:G162GK9U4W)

Tilgængelig fra:

Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.

INN (International Name):

LEFLUNOMIDE

Sammensætning:

LEFLUNOMIDE 10 mg

Indgivelsesvej:

ORAL

Recept type:

PRESCRIPTION DRUG

Terapeutiske indikationer:

Leflunomide tablets, USP are indicated for the treatment of adults with active rheumatoid arthritis (RA). Leflunomide tablets are contraindicated in: •Pregnant women.  Leflunomide may cause fetal harm.  If a woman becomes pregnant while taking this drug, stop leflunomide, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see Warnings and Precautions (5.1and 5.3) and Use in Specific Populations (8.1)]. •Patients with severe hepatic impairment [see Warnings and Precautions (5.2)] . •Patients with known hypersensitivity to leflunomide or any of the other components of leflunomide tablets. Known reactions include anaphylaxis [see Adverse Reactions (6.1)] . •Patients being treated with teriflunomide [see Drug Interactions (7)] . Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to leflunomide during pregnancy.  Health care providers and patients are encouraged to report pregnancies by calling 1-877-3

Produkt oversigt:

How Supplied Leflunomide Tablets, USP Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Protect from light.

Autorisation status:

Abbreviated New Drug Application

Produktets egenskaber

LEFLUNOMIDE - LEFLUNOMIDE TABLET
HERITAGE PHARMACEUTICALS INC. D/B/A AVET PHARMACEUTICALS INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
LEFLUNOMIDE TABLETS,
USP
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
LEFLUNOMIDE TABLETS, USP.
LEFLUNOMIDE TABLETS, USP FOR ORAL USE
INITIAL U.S. APPROVAL: 1998
WARNING: EMBRYO-FETAL TOXICITY AND HEPATOTOXICITY
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
EMBRYO-FETAL TOXICITY
TERATOGENICITY AND EMBRYO-LETHALITY OCCURRED IN ANIMALS ADMINISTERED
LEFLUNOMIDE.
(5.1, 8.1)
EXCLUDE PREGNANCY PRIOR TO INITIATING LEFLUNOMIDE TABLETS THERAPY.
(5.1, 8.3)
ADVISE USE OF EFFECTIVE CONTRACEPTION IN FEMALES OF REPRODUCTIVE
POTENTIAL DURING
TREATMENT AND DURING A DRUG ELIMINATION PROCEDURE. (5.1, 5.3, 8.3)
STOP LEFLUNOMIDE TABLETS AND USE AN ACCELERATED DRUG ELIMINATION
PROCEDURE IF THE
PATIENT BECOMES PREGNANT. (5.1, 5.3, 8.1)
HEPATOTOXICITY
SEVERE LIVER INJURY AND FATAL LIVER FAILURE HAVE BEEN REPORTED. (5.2)
AVOID LEFLUNOMIDE USE IN PATIENTS WITH PRE-EXISTING LIVER DISEASE, OR
THOSE WITH
SERUM ALANINE AMINOTRANSFERASE (ALT) >2XULN. (5.2, 8.6)
USE CAUTION WHEN LEFLUNOMIDE IS GIVEN WITH OTHER POTENTIALLY
HEPATOTOXIC DRUGS.
(5.2)
MONITOR ALT LEVELS. INTERRUPT LEFLUNOMIDE TREATMENT IF ALT ELEVATION >
3 FOLD ULN. IF
LIKELY LEFLUNOMIDE-INDUCED, START ACCELERATED DRUG ELIMINATION
PROCEDURE AND
MONITOR LIVER TESTS WEEKLY UNTIL NORMALIZED. (5.2, 5.3)
INDICATIONS AND USAGE
Leflunomide tablets, USP are a pyrimidine synthesis inhibitor
indicated for the treatment of adults with
active rheumatoid arthritis. (1)
DOSAGE AND ADMINISTRATION
Loading dosage for patients at low risk for leflunomide -associated
hepatotoxicity and leflunomide -
associated myelosuppression: 100 mg daily for 3 days. (2.1)
Maintenance dosage: 20 mg daily. (2.1)
Maximum recommended daily dosage: 20 mg once daily. (2.1)
If 20 mg once daily is not tolerated, may decrease dosage to 10 mg
once daily. (2.1)
Screen patients for activ